
    
      Study C1071001 is a Phase 1, open label, multi dose, multi center, dose escalation, safety,
      pharmacokinetic (PK) and pharmacodynamic study of PF-06863135 in adult patients with advanced
      multiple myeloma who have relapsed from or are refractory to standard therapy. This is a two
      part study; Part 1 will assess the safety and tolerability of increasing dose levels of
      PF-06863135 and Part 2 will evaluate safety and anti-myeloma activity of PF-06863135 at the
      RP2Ds determined in Part 1.
    
  